SCHEMBL4363572

SCHEMBL4363572

CCOc1ccccc1[C](c1ccccc1)c1ccccc1OCC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
RAB9A P51151 2/20 0.54
HCRTR1 O43613 2/20 0.53
ALDH1A1 P00352 3/20 0.51
HPGD P15428 1/20 0.51
HSD17B10 Q99714 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
GLA P06280 1/20 0.50
MAPT P10636 3/20 0.46
MRGPRX4 Q96LA9 1/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
MAPK1 P28482 1/20 0.46
NPSR1 Q6W5P4 2/20 0.45
KCNK3 O14649 1/20 0.45
KCNK9 Q9NPC2 1/20 0.45
ATM Q13315 1/20 0.45
GPR55 Q9Y2T6 1/20 0.45
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4366694 0.96 MEN1 (0.56) MEN1KMT2ARAB9AHCRTR1ALDH1A1
SCHEMBL2490797 0.88 HCRTR1 (0.59) MEN1KMT2ARAB9AHCRTR1ALDH1A1
SCHEMBL4367374 0.85 KMT2A (0.50) MEN1KMT2AALDH1A1L3MBTL1MAPT
SCHEMBL4366626 0.84 LMNA (0.54) MEN1KMT2AALDH1A1L3MBTL1MAPT
SCHEMBL3432995 0.82 KDM4E (0.55) MEN1KMT2ARAB9AHCRTR1ALDH1A1
SCHEMBL30033997 0.81 RAB9A (0.67) MEN1KMT2ARAB9AHCRTR1ALDH1A1
SCHEMBL4362613 0.81 KMT2A (0.50) MEN1KMT2AALDH1A1L3MBTL1MAPT
SCHEMBL720460 0.81 RAB9A (0.67) MEN1KMT2ARAB9AHCRTR1ALDH1A1
SCHEMBL9715756 0.80 MEN1 (0.52) MEN1KMT2ARAB9AHCRTR1ALDH1A1
SCHEMBL4365539 0.80 LMNA (0.54) MEN1KMT2AALDH1A1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2749566-B1 SOLID-PHASE CARRIER FOR AMINATED OLIGONUCLEOTIDE AIST (JP) 2018-05-09 EP disclosed
US-9428809-B2 Solid-phase carrier for aminated oligonucleotide NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2016-08-30 US disclosed
US-20140187724-A1 SOLID-PHASE CARRIER FOR AMINATED OLIGONUCLEOTIDE NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2014-07-03 US disclosed
EP-2749566-A1 SOLID-PHASE CARRIER FOR AMINATED OLIGONUCLEOTIDE National Institute of Advanced Industrial Science And Technology (JP) 2014-07-02 EP disclosed
EP-1908829-B1 OLIGONUCLEOTIDE PROBE NAT INST OF ADVANCED IND SCIEN (JP) 2014-01-08 EP disclosed
US-7491857-B2 Oligonucleotide probe NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2009-02-17 US disclosed
US-20080227968-A1 Oligonucleotide Probe NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2008-09-18 US disclosed
EP-1908829-A1 OLIGONUCLEOTIDE PROBE National Institute of Advanced Industrial Science and Technology (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227968-A1 Oligonucleotide Probe APEX1, RNGTT, RNASEH1 MEN1 1946/4885KMT2A 3173/4885RAB9A 4788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.